概要

研究と設備

教育と学生生活

受験生の方へ(学部/大学院)

Research / Equipment

研究と設備

HOME

研究と設備

研究者紹介

研究者紹介

<戻る

附属創薬センター
創薬臨床研究推進ユニット
構造展開ユニット

北崎 智幸特任准教授(常勤)

製薬企業でのメディシナルケミストとしての創薬経験を活かしてアカデミア発の創薬に貢献します。薬学研究科の創薬サイエンス研究支援拠点においてBINDS(創薬等先端技術支援基盤プラットフォーム)事業を展開し、全国の創薬研究のサポートをしていきます。

【学歴】
1987 九州大学大学院工学研究科合成化学専攻修士課程修了
2000 九州大学大学院工学研究科博士(工学)

【職歴】
1987 武田薬品工業株式会社 化学研究所
2017 Axcelead Drug Discovery Partners株式会社
2022 大阪大学大学院薬学研究科構造展開ユニット

【受賞歴】
2006 日本薬学会医薬化学部会 部会賞

研究テーマ

アカデミアシーズ等に基づく創薬支援

アカデミアシーズ等を医薬品候補に育成するため、製薬企業で培った知見・技術を用いて創薬研究支援を進める。
1.コンサルティングによる支援依頼者の課題抽出とBINDS支援による解決策の提示及び実施
2.効率的な研究支援のためのBINDS内外との連携拡大
3.BINDS支援拡大のためのアウトリーチ活動

代表的な業績

Discovery of a novel series of medium-sized cyclic enteropeptidase inhibitors
Fumiaki Kikuchi, Zenichi Ikeda, Keiko Kakegawa, Youichi Nishikawa, Shigekazu Sasaki, Koichiro Fukuda, Kazuaki Takami, Yoshihiro Banno, Hitoaki Nishikawa, Naohiro Taya, Takashi Nakahata, Sachiko Itono, Hiroaki Yashiro, Kazue Tsuchimori, Hideyuki Hiyoshi, Masako Sasaki, Kimio Tohyama, Kouta Matsumiya, Youko Ishihara, Tetsuji Kawamoto, Masahiro Kamaura, Masanori Watanabe, Tomoyuki Kitazaki, Tsuyoshi Maekawa, Minoru Sasaki
Bioorg. Med. Chem. 2023, 93, 117462-117479.

Design, Synthesis, and Biological Evaluation of a Novel Series of 4‑Guanidinobenzoate Derivatives as Enteropeptidase Inhibitors with Low Systemic Exposure for the Treatment of Obesity
Zenichi Ikeda, Keiko Kakegawa, Fumiaki Kikuchi, Sachiko Itono, Hideyuki Oki, Hiroaki Yashiro, Hideyuki Hiyoshi, Kazue Tsuchimori, Kenichi Hamagami, Masanori Watanabe, Masako Sasaki, Youko Ishihara, Kimio Tohyama, Tomoyuki Kitazaki, Tsuyoshi Maekawa, and Minoru Sasaki
J. Med. Chem. 2022, 65, 8456-8477.

Discovery of a novel series of GPR119 agonists: Design, synthesis, and biological evaluation of N-(Piperidin-4-yl)-N-(trifluoromethyl) pyrimidin-4-amine derivatives
Osamu Kubo, Kazuaki Takami, Masahiro Kamaura, Koji Watanabe, Hirohisa Miyashita, Shinichi Abe, Kae Matsuda, Yoshiyuki Tsujihata, Tomoyuki Odani, Shinji Iwasaki, Tomoyuki Kitazaki, Toshiki Murata, Kenjiro Sato
Bioorg. Med. Chem. 2021, 41, 116208-116221.

Inhibition of MGAT2 modulates fat-induced gut peptide release and fat intake in normal mice and ameliorates obesity and diabetes in ob/ob mice fed on a high-fat diet
Taisuke Mochida, Kazumi Take, Toshiyuki Maki, Masanori Nakakariya, Ryutaro Adachi, Kenjiro Sato, Tomoyuki Kitazaki, Shiro Takekawa
FEBS Open Bio 10(2020) 316-326.

Pharmacological inhibition of monoacylglycerol o-Acyltransferase 2 improves hyperlipidemia, obesity, and diabetes by change in intestinal fat utilization
Kazumi Take, Taisuke Mochida, Toshiyuki Maki, Yoshinori Satomi, Megumi Hirayama, Masanori Nakakariya, Nobuyuki Amano, Ryutaro Adachi, Kenjiro Sato, Tomoyuki Kitazaki, Shiro Takekawa
PLoS ONE 2016; 11(3), 1-18.

Optimization of a novel series of N-phenylindoline-5-sulfonamide-based acyl CoA:monoacylglycerol acyltransferase-2 inhibitors: Mitigation of CYP3A4 time-dependent inhibition and phototoxic liabilities
Kenjiro Sato, Hiroki Takahagi, Osamu Kubo, Kousuke Hidaka, Takeshi Yoshikawa, Masahiro Kamaura, Masanori Nakakariya, Nobuyuki Amano, Ryutaro Adachi, Toshiyuki Maki, Kazumi Take, Shiro Takekawa, Tomoyuki Kitazaki, Tsuyoshi Maekawa
Bioorg. Med. Chem. 2015, 23, 4544-4560.

Discovery of a Novel Series of N‑Phenylindoline-5-sulfonamide Derivatives as Potent, Selective, and Orally Bioavailable Acyl CoA:Monoacylglycerol Acyltransferase‑2 Inhibitors
Kenjiro Sato, Hiroki Takahagi, Takeshi Yoshikawa, Shinji Morimoto, Takafumi Takai, Kousuke Hidaka, Masahiro Kamaura, Osamu Kubo, Ryutaro Adachi, Tsuyoshi Ishii, Toshiyuki Maki, Taisuke Mochida, Shiro Takekawa, Masanori Nakakariya, Nobuyuki Amano, and Tomoyuki Kitazaki
J. Med. Chem. 2015, 58, 3892-3909.

Discovery of 1-{4-[1-(2,6-Difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a Potent, Orally Active, Non-Peptide Antagonist of the Human Gonadotropin-Releasing Hormone Receptor
Kazuhiro Miwa, Takenori Hitaka, Takashi Imada, Satoshi Sasaki, Mie Yoshimatsu, Masami Kusaka, Akira Tanaka, Daisuke Nakata, Shuichi Furuya, Satoshi Endo, Kazumasa Hamamura, and Tomoyuki Kitazaki
J. Med. Chem. 2011, 54, 4998-5012.

A novel cyclohexene derivative, ethyl (6R)-6-[N-(2-chloro-4-fluorophenyl) sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling
Masayuki Ii, Naoko Matsunaga, Kaoru Hazeki, Kazuyo Nakamura, Katsunori Takashima, Tsukasa Seya, Osamu Hazeki, Tomoyuki Kitazaki, Yuji Iizawa
Molecular Pharmacology 2006, 69(4) 1288-1295.

Discovery of Novel and Potent Small-Molecule Inhibitors of NO and Cytokine Production as Antisepsis Agents: Synthesis and Biological Activity of Alkyl 6-(N-Substituted sulfamoyl)cyclohex-1-ene-1-carboxylate
Masami Yamada, Takashi Ichikawa, Masayuki Ii, Mie Sunamoto, Katsumi Itoh, Norikazu Tamura, and Tomoyuki Kitazaki
J. Med. Chem. 2005, 48, 7457-7467.